GSK Jemperli shows survival benefit in uterus cancer, meets main goal of phase 3 trial

Friday, 2 December 2022, 11:40:38
GSK (GSK) said its medicine Jemperli (dostarlimab) met the main goal of progression-free survival ((PFS)) in patients with primary advanced or recurrent endometrial cancer in a phase…
— Seeking Alpha

GSK bone marrow cancer therapy momelotinib gets review in EU

Friday, 2 December 2022, 11:03:45
The European Medicines Agency ((EMA)) accepted for review GSK”s (GSK) application seeking approval of oral therapy momelotinib to treat myelofibrosis.The British pharma giant said…
— Seeking Alpha

GlaxoSmithKline PT Lowered to GBP15.50 at Citi

Friday, 2 December 2022, 10:20:09
https://www.investing.com/news/pro/glaxosmithkline-pt-lowered-to-gbp1550-at-citi-432SI-2956159
— Investing.com

GSK makes headway with two cancer drugs after double-barrelled setback last month

Friday, 2 December 2022, 10:12:39
GlaxoSmithKline (GSK) is making “significant” headway with two of its cancer drugs, following a double-barrelled setback in its oncology efforts last month. The British pharmaceutical giant’s bone marrow cancer treatment Momelotinib this morning received marketing approval from the European Medicines Agency, following an application to the FDA in the US in August. If approved by […] The post GSK makes headway with two cancer drugs after double-barrelled setback last month appeared first on CityAM .
— City AM

GSK :EMA Accepts Marketing Authorization Application For Momelotinib For Rare Blood Cancer Treatment

Friday, 2 December 2022, 09:16:00
LONDON (dpa-AFX) – GSK plc (GSK.L, GSK) said Friday that the European Medicines Agency has accepted the marketing authorization application for momelotinib for the treatment of myelofibrosis.The a…
— Finanz Nachrichten